GSK2302024A (WT1-A10 + AS15 ASCI)
Двойное слепое, рандомизированное, плацебо-контролируемое исследование I/II фазы по изучению безопасности, иммуногенности и клинической активности неоадъювантной терапии антигенспецифичным противоопухолевым иммунотерапевтическим средством WT1-A10 + AS15 в комбинации со стандартной терапией у больных с WT1-положительным раком молочной железы II или III стадии
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/326/2012-09-10/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда
Простыми словами
Словарь терминов- Совмещённое исследование фаз Фаза I–II: Фаза I — первое применение у людей. Проверяют безопасность и подбирают дозу, участников немного. Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 35 чел. в стране «Россия».
- Центров в реестре: 3 в 2 городах. Список — ниже на странице.
- Плановая дата окончания (06.2015) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Состояние пациента (ECOG)0–1
- Биомаркеры в критерияхHER2, Гормональные рецепторы (ER/PR)
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 25 · невключение: 13
Критерии включения
- The patient is ≥ 18 years of age at the time the informed consent to screening has been obtained.
- The patient has proven T1 with lymph node involvement or T2-T4c, any N, M0 primary invasive breast cancer, histologically confirmed by core needle biopsy.
- Isolated supraclavicular lymph node involvement is allowed.
- The patient's tumor shows WT1 antigen expression.
- The patient has one of the following histologically confirmed breast cancer subtypes:
- Estrogen receptor and/or progesterone positive tumor.
- Human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.
- HER2-negative breast cancer.
- Eastern Cooperative Oncology Group (performance status of 0 or 1 at the time of study treatment allocation.
- Baseline left ventricular ejection fraction of ≥ 50% as measured within six weeks prior to study treatment allocation by echocardiography or multi-gated acquisition(MUGA)scan.
- The patient shows normal organ function according to the following parameters(as measured within six weeks prior to treatment allocation)::
- Hemoglobin: Within normal range according to institutional standards.
- Absolute leukocyte count: Within normal range according to institutional standards.
- Absolute lymphocyte count: Within normal range according to institutional standards.
- Platelet count: Within normal range according to institutional standards
- Alanine aminotransferase: ≤ 2.5 x Upper Limit of Normal (ULN)
- Aspartate aminotransferase: ≤ 2.5 x ULN
- Total bilirubin: ≤ 1.5 x ULN. In the case of known Gilbert's syndrome ≤ 2 x ULN
- Serum creatinine: 1.5 x ULN
- Calculated creatinine clearance: > 50 mL/min
- A female patient of childbearing potential may be enrolled in the study, if the patient:
- has practiced adequate contraception for 30 days prior to study product administration, and
- has a negative pregnancy test within one week prior to treatment allocation and
- has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the study product administration series.In view of the investigator, the patient can and will comply with the requirements of the protocol.
- Written informed consent has been obtained from the patient prior to performance of any study specific procedure.
Критерии невключения
- The patient has inflammatory breast cancer, which is defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion.
- Diagnosis established by incisional biopsy.
- Prior and concomitant neoadjuvant anti-breast-cancer treatments such as chemotherapy, immunotherapy / biological response modifiers, endocrine therapy, and radiotherapy, unless authorized specifically by the protocol.
- The patient is known to be human immunodeficiency virus -positive.
- The patient has symptomatic autoimmune disease such as, but not limited to multiple sclerosis, lupus, and inflammatory bowel disease. Patients with vitiligo are not excluded.
- The patient is known to have difficult-to-control hypertension, coronary artery disease, arrhythmia requiring treatment, clinically significant valvular disease, cardiomegaly on chest X-ray, ventricular hypertrophy on electrocardiogram or previous myocardial infarction or congestive heart failure.
- The patient has a history of allergic reactions likely to be exacerbated by any component of the investigational product used in the study.
- The patient has other concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.
- The patient has (or has had) previous or concomitant malignancies at other sites, except effectively treated malignancy that is considered by the investigator highly likely to have been cured.
- The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent or to comply with the study procedures.
- The patient has received any investigational or non-registered product within 30 days preceding the first dose of study products or planned use during the study period.
- The patient requires concomitant treatment with any immunosuppressive agents or with systemic corticosteroids prescribed for chronic treatment.
- The patient has a significant disorder of coagulation or receives treatment with warfarin derivatives or heparin. Patients receiving individual doses of low molecular weight heparin outside of 24 hours prior to WT1-A10 + AS15 ASCI/placebo administration are eligible. Patients receiving prophylactic antiplatelet medications e.g. low-dose aspirin, and without a clinically-apparent bleeding tendency are eligible.
Источник: ClinicalTrials.gov, NCT01220128 · запись обновлена в реестре 25 мая 2021.
Дизайн и результаты
Что измеряют — первичные конечные точки (10)
- Number of Subjects With Severe Toxicities — From Week 0 to Week 26/32 (period starting from GSK2302024A/placebo treatment allocation and ending with the concluding Visit i.e.: Week 26 for patients receiving 6 injections and Week 32 for patients receiving 8 injections)
- Number of Patients With an Anti-Wilm's Tumor Gene (Anti-WT1) Humoral Response — At post-GSK2302024A/placebo Dose 4 (Week 13)
- Number of Patients With Adverse Events (AEs) — During the treatment period and up to 30 days post last administration
- Number of Subjects With Serious Adverse Events SAE(s) — From Week 0 to Week 26/32 (period starting from GSK2302024A/placebo treatment allocation and ending with the concluding Visit i.e.: Week 26 for patients receiving 6 injections and Week 32 for patients receiving 8 injections)
- Number of Subjects With Alanine Aminotransferase Increased Abnormality, by Common Terminology Criteria for Adverse Events (CTCAE) Maximum Grade — During the treatment period and up to 30 days post last administration
- Number of Subjects With Alkaline Phosphatase Increased Abnormality, by CTCAE Maximum Grade — During the treatment period and up to 30 days post last administration
- Number of Subjects With Anemia, by CTCAE Maximum Grade — During the treatment period and up to 30 days post last administration
- Number of Subjects With Aspartate Aminotransferase Increased Abnormality, by CTCAE Maximum Grade — During the treatment period and up to 30 days post last administration
- Number of Subjects With Blood Bilirubin Increased Abnormality, by CTCAE Maximum Grade — During the treatment period and up to 30 days post last administration
- Number of Subjects With Creatine Increased Abnormality, by CTCAE Maximum Grade — During the treatment period and up to 30 days post last administration
Цель исследования
The purpose of this study is to evaluate the safety, immunogenicity and clinical activity of a new WT1 anti-cancer immunotherapy in patients with WT1-positive Stage II or III breast cancer. The treatment will be given before surgery in combination with standard therapy.
Области и заболевания
Где проходит
3 центра в 2 городахОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 326 от 10.09.2012 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик, центры
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01220128 Официальный реестр (США) · загружено 9 ноября 2026Цель
-
clinmarket · № 5748 Каталог исследований · загружено 1 октября 2026Статус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.